Nanjing Vazyme Biotech Co Ltd Capital Reinvestment Ratio
Nanjing Vazyme Biotech Co Ltd capital reinvestment ratio. Nanjing Vazyme Biotech Co Ltd (688105) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥75.30 Million) in capital expenditures (CN¥15.83 Million). Check 688105 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Nanjing Vazyme Biotech Co Ltd (2019–2025)
Capital reinvestment ratio of Nanjing Vazyme Biotech Co Ltd from 2019 to 2025. This chart tracks Nanjing Vazyme Biotech Co Ltd's Capital Reinvestment Ratio across 6 annual periods. Also explore Nanjing Vazyme Biotech Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Nanjing Vazyme Biotech Co Ltd Capital Reinvestment Ratio by Year (2019–2025)
Nanjing Vazyme Biotech Co Ltd capital reinvestment ratio by year from 2019 to 2025. For the full cash flow conversion analysis, see 688105 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥233.16 Million | CN¥47.39 Million | ▼ -82.7% |
| 2023 | 1.17x | CN¥198.40 Million | CN¥232.90 Million | ▼ -10.4% |
| 2022 | 1.31x | CN¥735.17 Million | CN¥962.86 Million | ▲ +208.4% |
| 2021 | 0.42x | CN¥616.80 Million | CN¥261.96 Million | ▲ +123.7% |
| 2020 | 0.19x | CN¥803.55 Million | CN¥152.54 Million | ▼ -85.5% |
| 2019 | 1.31x | CN¥15.20 Million | CN¥19.88 Million | — |